New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:01 EDTNYMXNymox reports update on nerve sparing in men treated with NX-1207
Nymox Pharmaceutical reports new data supporting the positive sexual functional preservation profile of NX-1207, the company's lead compound in Phase 3 development for the treatment of prostate enlargement and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments. The nerve-sparing findings are consistent with results from earlier studies which have shown evidence of sexual functional preservation in men after NX-1207 treatment, including 1) patient reports of no significant new clinical sexual problems, 2) no change in blood testosterone levels, and 3) sexual function questionnaire data showing no sexual side effects from NX-1207 treatment.
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:32 EDTNYMXNymox announces positive efficacy results in Phase 3 trial of NX-1207
Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.
July 15, 2014
09:31 EDTNYMXNymox completes enrollment for second BPH re-injection study
Nymox Pharmaceutical announced the closing of enrollment for Study NX02-0022, the company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate. The NX02-0022 study enrolled patients who had previously participated in an earlier NX-1207 BPH study, and in the new trial these men received a second open-label injection of NX-1207. The study used a new lyophilized formulation of NX-1207 that has longer stability stored at room temperature. An interim analysis of the new efficacy data from the NX02-0022 study will be reported within the next few weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use